Announcements
- MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
- MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
- MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
- MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
- MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
- MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
- MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
- MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
- MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
- MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
More ▼
Key statistics
On Tuesday, MoonLake Immunotherapeutics (MLTXN:MEX) closed at 977.05, -5.12% below its 52-week high of 1,029.82, set on Oct 03, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 977.05 |
---|---|
High | 977.05 |
Low | 977.05 |
Bid | 1,089.96 |
Offer | 750.00 |
Previous close | 711.11 |
Average volume | 0.00 |
---|---|
Shares outstanding | 63.87m |
Free float | 56.94m |
P/E (TTM) | -- |
Market cap | 2.89bn USD |
EPS (TTM) | -0.7623 USD |
Data delayed at least 20 minutes, as of Jan 09 2024 11:30 GMT.
More ▼